Form 4: CalciMedica Director Fred Middleton Granted New Stock Options Following Shareholder Approval

CalciMedica, Inc. (CALC) reported that Director and 10% Owner Fred A. Middleton was granted a total of 46,249 stock options on June 24, 2025, following shareholder approval of the Amended 2023 Equity Incentive Plan.

Summary

• Fred A. Middleton, a Director and 10% Owner of CalciMedica, Inc. (CALC), was granted new stock options on June 24, 2025.
• The grants include four separate tranches of Director Stock Options (Right to Buy).
• Three tranches, totaling 36,249 shares (10,000, 6,562, and 19,687 shares), have an exercise price of $1.53 per share and expire on April 22, 2035.
• The remaining tranche of 10,000 shares has an exercise price of $1.65 per share and expires on June 23, 2035.
• The option grants were initially approved by the Board of Directors on April 23, 2025, contingent on stockholder approval of an amendment to the Company's 2023 Equity Incentive Plan (the 'Amended 2023 EIP').
• Stockholders approved the Amended 2023 EIP on June 24, 2025, enabling the grants.
• Vesting schedules vary: 10,000 shares (at $1.53) vest 1/12th monthly over one year from March 26, 2025; 6,562 shares (at $1.53) are immediately exercisable; 19,687 shares (at $1.53) vest 1/9th monthly over one year from April 1, 2025.
• The 10,000 shares (at $1.65) vest 1/12th monthly over one year from June 24, 2025, and will be fully vested by the Company's 2026 annual meeting of stockholders.
• Following these transactions, Fred A. Middleton directly beneficially owns 46,249 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The document reports a routine and expected insider transaction (stock option grants) following shareholder approval of an equity plan. This is generally a neutral to slightly positive event as it aligns director interests with shareholders, but does not convey significant new financial performance or strategic shifts.

Positives

• The grant of stock options to a director and 10% owner aligns management and significant shareholder interests with the long-term performance of the company.
• Shareholder approval of the Amended 2023 Equity Incentive Plan demonstrates support for the company's compensation strategy and ability to attract and retain talent.

Negatives

• The issuance of new stock options, if exercised, could lead to a minor dilution of existing shareholder equity, although this is a standard practice for equity compensation.

Risks

• Potential future dilution of common stock if the granted options are exercised, increasing the total number of outstanding shares.
• The value of the options is dependent on the future stock price of CalciMedica, which is subject to market volatility and company performance.

Future Outlook

The future outlook indicates continued equity-based compensation for key personnel, with vesting schedules extending over the next year, aligning the director's interests with the company's long-term performance. The full vesting of one option tranche by the 2026 annual meeting suggests a continued focus on future performance milestones.

Management Comments

• The option grant was approved by the Board of Directors of CalciMedica, Inc. on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan.
• The Company's stockholders approved the Amended 2023 EIP on June 24, 2025.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, as well as other sectors, to incentivize long-term commitment and align the interests of leadership with those of shareholders. This filing reflects a routine compensation event within the industry.

Comparison to Industry Standards

• The use of stock options as a component of director compensation is a standard practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• Vesting schedules, such as monthly installments over one year, are typical for equity grants designed to retain talent and incentivize sustained performance.
• The exercise prices of $1.53 and $1.65 are reflective of the company's stock price at or around the grant date, which is standard for 'at-the-money' or 'in-the-money' option grants.

Corporate Governance

Related Party Transactions

• The grant of stock options to Fred A. Middleton, a Director and 10% Owner, constitutes a related party transaction as it involves compensation provided to an insider.

Stakeholder Impact

• Shareholders: Potential for minor dilution upon exercise of options, but also benefit from increased alignment of director's interests with long-term company performance.
• Employees: The approval of the Amended 2023 EIP may signal a broader commitment to equity-based compensation, potentially benefiting other employees in the future.
• Management/Directors: Direct benefit through equity compensation, incentivizing continued service and performance.

Next Steps

• Continued vesting of the granted stock options according to their respective schedules, with some options vesting monthly over the next year.
• The 10,000 shares granted at an exercise price of $1.65 will be fully vested by the Company's 2026 annual meeting of stockholders.

Key Dates

Keywords

CalciMedica, CALC, SEC Form 4, Stock Options, Director Compensation, Equity Incentive Plan, Insider Transaction, Shareholder Approval, Vesting Schedule, Derivative Securities